Qiagen stock at EUR 40.25 with a 23.2 P/ E ratio

Published on 10/09/2026 at 15:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock costs EUR 40.25 on October 9, 2026 after EUR 39.78. Market value is USD 9.3 billion, with earnings estimated November 3, 2026.

Key points in brief

Qiagen stock was at EUR 40.25 at Lang & Schwarz on October 9, 2026, up 1.18 percent versus EUR 39.78.
The NYSE quote was USD 45.27 on October 9, 2026, within a 52-week range of USD 32.53 to USD 57.82.
Fintel reported a consensus target mean of EUR 41.94 on October 3, 2026, 4.20 percent above the Lang & Schwarz price.
MarketBeat lists November 3, 2026 as the next estimated earnings date.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock was trading at EUR 40.25 at Lang & Schwarz on October 9, 2026 at 3:36 p.m. CEST, up 1.18 percent versus the prior close of EUR 39.78. The move places the euro quotation back above the EUR 40.00 mark during the regular Xetra session.

Intraday price and range

Qiagen was last at USD 45.27 on the NYSE on October 9, 2026 at 9:41 a.m. EDT. The same quotation carried a 52-week range of USD 32.53 to USD 57.82, while trading volume stood at 62,753 shares against an average of 2,579,196 shares.

The primary-market quote was up 1.65 percent from a prior close of USD 44.53 at that timestamp. This foreign-currency move is separate from the EUR 40.25 Lang & Schwarz quotation and is not combined with its daily percentage.

Valuation and analyst target

Qiagen's market capitalization was USD 9.3 billion on October 9, 2026. The P/E ratio was 23.23 and the trailing dividend yield was 0.06 percent, giving the valuation paragraph a clear numerical anchor for the session.

According to Fintel on October 3, 2026, the consensus target mean was EUR 41.94, up from EUR 40.19 on September 15, 2026. The target lies 4.20 percent above the Lang & Schwarz price, while the mean recommendation data cited by Fintel covered 23 analyst recommendations on September 1, 2026.

Comparison with peers

Qiagen (NYSE, USD): plus 1.18 percent, P/E 23.23, market capitalization USD 9.3 billion

Thermo Fisher Scientific (NYSE, USD): plus 1.0 percent, P/E 35.34, market capitalization USD 243.4 billion

Danaher (NYSE, USD): plus 1.1 percent, P/E 38.95, market capitalization USD 154.6 billion

Next scheduled date

MarketBeat lists November 3, 2026 as Qiagen's next estimated earnings date. That date gives the market a scheduled reference point after the second-quarter reporting period.

Qiagen stock at EUR 40.25

Qiagen stock was trading at EUR 40.25 at Lang & Schwarz on October 9, 2026 at 3:36 p.m. CEST, plus 1.18 percent versus the prior close of EUR 39.78. The primary-market quote was USD 45.27 on the NYSE at 9:41 a.m. EDT.
The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.